| 1 |
33555084 | Practice Patterns for Prevention of Chemotherapy-Induced Nausea and Vomiting and Antiemetic Guideline Adherence Based on Real-World Prescribing Data. | 2021 Jun |
1 |
| 2 |
34789076 | Efficacy of ondansetron against emesis induced by a multiple-day cisplatin-based chemotherapy regimen for malignant lymphoma. | 2021 Dec |
1 |
| 3 |
32740273 | Management of cisplatin-associated toxicities in bladder cancer patients. | 2020 Sep |
1 |
| 4 |
28691209 | Efficacy of the oral neurokinin-1 receptor antagonist aprepitant for nausea and vomiting induced by cisplatin and carboplatin in Japanese patients with gynecological cancer. | 2017 Oct |
1 |
| 5 |
26476625 | Defining the efficacy of neurokinin-1 receptor antagonists in controlling chemotherapy-induced nausea and vomiting in different emetogenic settings-a meta-analysis. | 2016 May |
1 |
| 6 |
26952945 | Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial. | 2016 Apr |
1 |
| 7 |
27334131 | Efficacy benefit of an NK1 receptor antagonist (NK1RA) in patients receiving carboplatin: supportive evidence with NEPA (a fixed combination of the NK1 RA, netupitant, and palonosetron) and aprepitant regimens. | 2016 Nov |
1 |
| 8 |
24641692 | Involvement of substance P in the development of cisplatin-induced acute and delayed pica in rats. | 2014 Jun |
2 |
| 9 |
23001014 | Cisplatin causes over-expression of tachykinin NK(1) receptors and increases ERK1/2- and PKA- phosphorylation during peak immediate- and delayed-phase emesis in the least shrew (Cryptotis parva) brainstem. | 2013 Jan 5 |
5 |
| 10 |
23863648 | [Comparative study of an antiemetic NK1 receptor-antagonist in lung cancer patients treated with divided doses for Cisplatin]. | 2013 Jun |
1 |
| 11 |
27713384 | Mechanisms of Broad-Spectrum Antiemetic Efficacy of Cannabinoids against Chemotherapy-Induced Acute and Delayed Vomiting. | 2010 Sep 3 |
1 |
| 12 |
16872268 | The neurokinin1 receptor antagonist aprepitant as an antiemetic for moderately emetogenic chemotherapy. | 2006 Aug |
1 |
| 13 |
14746859 | The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials. | 2004 Feb |
2 |
| 14 |
18628185 | Inhibiting substance p pathway for prevention of chemotherapy-induced emesis: preclinical data, clinical trials of neurokinin-1 receptor antagonists. | 2004 Jan 1 |
1 |
| 15 |
14559891 | Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. | 2003 Nov 15 |
1 |
| 16 |
11497388 | Potential role of the NK1 receptor antagonists in chemotherapy-induced nausea and vomiting. | 2001 Jul |
1 |
| 17 |
11700782 | A multinational study to measure the value that patients with cancer place on improved emesis control following cisplatin chemotherapy. | 2001 |
2 |
| 18 |
9804700 | Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist. | 1998 Nov 5 |
2 |
| 19 |
9063690 | The tachykinin NK1 receptor antagonist PD 154075 blocks cisplatin-induced delayed emesis in the ferret. | 1997 Feb 26 |
3 |
| 20 |
9182982 | Use of an NK1 receptor antagonist to prevent delayed emesis after cisplatin. | 1997 Jun 4 |
1 |